article Open AccessTop 1% cited
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Annals of the Rheumatic Diseases · 2020 · Vol. 79(6) · pp. 700–712
Laure Gossec✉(Inserm)Xenofon Baraliakos(Rheumazentrum Ruhrgebiet)Andreas Kerschbaumer(Klinik Hietzing)Maarten de Wit(European League Against Rheumatism)Iain McInnes(University of Glasgow)Maxime Dougados(Université Paris Cité)Jette Primdahl(University of Southern Denmark)Dennis McGonagle(University of Leeds)Daniel Aletaha(Medical University of Vienna)Andra Bălănescu(Carol Davila University of Medicine and Pharmacy)P Bálint(National Institute of Oncology)Heidi BertheussenWolf‐Henning Boehncke(University Hospital of Geneva)Gerd R Burmester(Charité - Universitätsmedizin Berlin)Juan D. Cañete(Hospital Clínic de Barcelona)Nemanja Damjanov(University of Belgrade)Tue Wenzel Kragstrup(Aarhus University)Tore K. Kvien(Diakonhjemmet Hospital)Robert Landewé(Zuyderland Medisch Centrum)Rik Lories(KU Leuven)Helena Marzo‐Ortega(University of Leeds)Denis Poddubnyy(German Rheumatism Research Centre)Santiago Rodrigues-Manica(Hospital de Egas Moniz)Georg Schett(Friedrich-Alexander-Universität Erlangen-Nürnberg)Douglas J. Veale(St. Vincent's University Hospital)Filip Van den Bosch(Ghent University)Désirée van der Heijde(Leiden University Medical Center)Josef S Smolen(Klinik Hietzing)
Abstract
These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.
Spondyloarthritis Studies and TreatmentsPsoriasis: Treatment and PathogenesisRheumatoid Arthritis Research and TherapiesMedicinePsoriatic arthritisIntensive care medicineAlternative medicineArthritisMEDLINEPsoriasisDermatologyInternal medicinePathology
MeSH terms
Janus Kinase InhibitorsSynthetic DrugsSystematic Reviews as TopicDecision Making, SharedAnti-Inflammatory Agents, Non-SteroidalBiological ProductsConsensus Development Conferences as TopicConsensus Statements as TopicEuropeGlucocorticoidsHumansSocieties, MedicalTumor Necrosis Factor-alphaArthritis, PsoriaticInterleukin-12
Funding
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Celgene
- Mylan
- National Institute for Health and Care Research
- European League Against Rheumatism
- Leeds Biomedical Research Centre
Citations
935
FWCI
114.24
field-weighted impact
References
100
Percentile
100%
vs. same field & year
Citations per year
Cited by
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Annals of the Rheumatic Diseases · 2022 · 832 citations
References
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Annals of the Rheumatic Diseases · 2016 · 910 citations
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Annals of the Rheumatic Diseases · 2015 · 1,431 citations
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
Annals of the Rheumatic Diseases · 2016 · 1,297 citations
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Journal of the American Academy of Dermatology · 2017 · 718 citations
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Journal of the American Academy of Dermatology · 2017 · 841 citations
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Annals of the Rheumatic Diseases · 2017 · 1,541 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.